052031
eIF4E (Eukaryotic Translation Initiation Factor 4E, eIF-4E, eIF-4F 25 kD Subunit, mRNA Cap-binding Protein)
Size
£594.00
- SKU:
- 052031
- Purity:
- Purified by affinity chromatography.
- Storage Conditions:
- -20°C
- Supplier:
- United States Biological
- Host:
- Mouse
- Immunogen:
- Purified full length recombinant protein corresponding to aa1-217 from human eIF4E, expressed in E. coli.
- Clone:
- P85D11B4
- Format:
- Supplied as a liquid in PBS, pH 7.2, 0.09% sodium azide.
- Extra Details:
- The initiation step of protein translation requires a number of eukaryotic translation initiation factors (eIFs). Initially, the 40S ribosomal subunit associates with Met-tRNAi and a group of initiation factors, including eIF1, eIF1A, eIF2, eIF3, and eIF5 to form the 43S pre-initiation complex. This complex is then recruited to the 5'-end of capped mRNA by another complex of factors (known as eIF4F) consisting of eIF4E, eIF4G, and eIF4A. eIF4E is an indispensable element for cap-dependent translation initiation and plays a major role in recognition of the mRNA cap structure. It binds to eIF4G, which serves as a scaffolding protein to gather eIF4A (ATP-dependent RNA helicase), eIF4B, eIF3, and poly-A-binding protein to form the 48S complex. This complex then scans the mRNA for an initiation codon and, once this is located, the 60S ribosomal subunit joins to form the elongation-competent fully functional 80S. eIF4E is the least abundant of the cellular translation initiation components and it represents the rate-limiting element for the initiation process. Under resting conditions, eIF4E is kept in an inactive form bound to 4E-binding proteins (4E-BPs); once the latter have been phosphorylated through the PI3K-AKT-mTOR signaling pathway, eIF4E is released and binds eIF4G to launch translation. eIF4E is upregulated in various human tumors, and it contributes to transformation, tumorigenesis, and cancer progression. eIF4E overexpression facilitates translation of weak and highly structured mRNAs that typically encode proteins involved in cancer biology, such as proto-oncoproteins (e.g. cyclin D1, ornithine decarboxylase), angiogenesis factors (e.g. FGF-2, VEGF), and factors related to tumor invasiveness, such as MMP-9. Therefore, eIF4E serves as an attractive cancer drug target. Applications: Suitable for use in Western Blot and Immunocytochemistry. Other applications not tested. Recommended Dilution: Western Blot: 0.1-1ug/ml Immunocytochemistry: 0.2-2ug/ml Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
- Shipping Conditions:
- Blue Ice